Search the Newsreel

Genesis Energy Reports Strong Q2 2026 Financial Results with Increased Revenue and Net Income

Genesis Energy, L.P. has filed its Form 10-Q for the second quarter ended June 30, 2026, with the U.S. Securities and Exchange Commission. The report details the company's financial results for both the three and six months ending on that date. The article suggests …

Artesian Resources declares quarterly dividend of $0.3199 By Investing.com

Artesian Resources Corporation (NASDAQ:ARTNA) has announced a regular quarterly dividend of $0.3199 per share for its Class A and Class B common stock. This dividend, which represents an annualized payout of $1.2796 per share, marks the company's 135th consecutive quarterly dividend. Payments are scheduled …

Artesian Resources Corporation Declares Third Quarter 2026 Common Stock Dividend

Artesian Resources Corporation announced a quarterly dividend of $0.3199 per share for its Class A and Class B common stock. This dividend, payable on August 28, 2026, to shareholders of record by August 17, 2026, marks the company's 135th consecutive quarterly payout. The annualized …

Artesian Resources Marks 135th Consecutive Quarterly Dividend

Artesian Resources (Nasdaq: ARTNA) has declared its 135th consecutive quarterly dividend, amounting to $0.3199 per share for the third quarter of 2026. This dividend, payable on August 28, 2026, to shareholders of record as of August 17, 2026, represents an annualized rate of $1.2796 …

Genesis Energy (NYSE: GEL) swings to Q2 profit as Segment Margin jumps

ARMOUR Residential REIT, Inc. (ARR) Stock Forecasts

This article provides an Argus research report summary for ARMOUR Residential REIT Inc. (ARR), outlining its operations in the U.S. and investments in various mortgage-backed securities. The report, dated August 5, 2026, includes current price and price target information for ARR, along with a …

Foresight Autonomous Holdings Ltd (FRSX) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Foresight Autonomous Holdings Ltd (FRSX), noting that no earnings forecast score is currently available. It highlights an average price target of $4.00 based on 0 analyst ratings, indicating a strong buy with an 867.74% upside. The piece …

Transcript : Genesis Energy, L.P., Q2 2026 Earnings Call, Aug 06, 2026

This article provides the transcript for Genesis Energy, L.P.'s Second Quarter 2026 Earnings Conference Call held on August 6, 2026. The content briefly notes that the transcript is reserved for subscribers, indicating detailed financial discussions. It also lists recent news and earnings reports related …

Uni President China Holdings (SEHK:220) Stock Faces Flat Profits And Dividend Strain

Press Release: Genesis Energy, L.P. Reports Second Quarter 2026 Results

Genesis Energy, L.P. has reported its second quarter 2026 results. This press release provides an overview of the company's financial performance during this period. The full details of the report are available in the attached document.

Chartwell Retirement Residences Stock Climbs 0.87% as Senior Housing Demand and Occupancy Growth Boost Investor Confidence

Cartesian Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Cartesian Therapeutics, Inc. announced its financial results for the second quarter and six months ended June 30, 2026. For the second quarter, the company reported a net income of $15.77 million. However, for the six-month period, the company posted a net loss of $23.41 …

Price to earnings forward of Radius Residential Care Ltd – NZX:RAD

Genesis Energy, L.P. Class A Common Units 2026 Q2 - Results - Earnings Call Presentation (NYSE:GEL) 2026-08-06

Genesis Energy's Q2 2026 performance met internal expectations, with a focus on strengthening its capital structure through asset sales and preferred security retirements. The company increased its quarterly distribution and outlined future annual cash savings. While the Offshore Pipeline Transportation segment faced temporary challenges, …

Is Genesis Energy LP (GEL) Undervalued After Q2 Earnings Report? GF Score: 60/100, Net Income of $42.9 Million

Acesian Partners Limited Reports Earnings Results for the Half Year Ended June 30, 2026

Cartesian Therapeutics Q2 2026 earnings: R&D spending rises as Phase 3 advances

Cartesian Therapeutics (NASDAQ: RNAC) reported Q2 2026 revenue of $0, with a diluted EPS of $0.46. The company experienced an increase in R&D spending due to the advancement of its Phase 3 AURORA trial, which widened its operating loss. However, a significant fair-value gain …

Krom Bank salurkan fasilitas kredit untuk ekspansi Pandai Gadai

Genesis Energy posts Q2 2026 net income $42.9M, revenue $532.0M; Available Cash before Reserves $78.3M

Genesis Energy reported its Q2 2026 financial results, with net income attributable to Genesis Energy reaching $42.9 million on revenue of $532.0 million. The company generated $180.7 million in Cash Flows from Operating Activities and $78.3 million in Available Cash before Reserves, covering quarterly …

Biodesix, Inc. Reports Impairment Loss on Intangible Assets for the Second Quarter Ended June 30, 2026

Biodesix, Inc. announced an impairment loss on intangible assets for the second quarter ended June 30, 2026. The reported impairment loss was $12,000, a decrease from $26,000 in the same period last year. This information was released on August 5, 2026, as part of …

Cartesian Therapeutics Reports Q2 2026 Results, Advances Descartes-08 Clinical Trials and WestGene In Vivo Partnership

Cartesian Therapeutics announced significant progress in its clinical trials for Descartes-08, a cell therapy for autoimmune diseases, including the Phase 3 AURORA trial for myasthenia gravis and Phase 2 TRITON trial for myositis, with data expected in Q1 and H1 2027, respectively. The company …

Cartesian Therapeutics reports Q2 2026: $149.3M cash; net income $15.8M; Phase 3 MG data expected 1Q27

Cartesian Therapeutics reported its Q2 2026 financial results, including $149.3 million in cash and a net income of $15.8 million. The company announced that its Phase 3 AURORA trial for Descartes-08 in myasthenia gravis is on track, with data expected in Q1 2027 and …

Cartesian Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Cartesian Therapeutics reported its Q2 2026 financial results, highlighting significant progress in its clinical pipeline and an extended cash runway into 2028. Key advancements include the Phase 3 AURORA trial for myasthenia gravis, a new strategic partnership with WestGene for an in vivo CAR-T …

Cartesian Therapeutics (Nasdaq: RNAC) Q2 earnings boosted by CVR revaluation

Genesis Energy (NYSE:GEL) Delivers Strong Q2 CY2026 Numbers

Genesis Energy (NYSE:GEL) Delivers Strong Q2 CY2026 Numbers Midstream energy infrastructure company Genesis Energy (NYSE:GEL) reported Q2 CY2026 results beating Wall Street's revenue expectations , with sales up 41% year on year to $532 million. Its GAAP profit of $0.26 per share was significantly …

Earnings Flash (GEL) Genesis Energy, L.P. Reports Q2 Revenue $532.0M

Genesis Energy, L.P. announced its Q2 2026 revenue of $532.0 million. The company's stock, GEL, is listed under Oil & Gas Transportation Services. This financial update follows previous earnings reports and analyst ratings for the company.

Genesis Energy Pays Down Credit Facility to Zero After $95M Sale

Artesian Resources declares Q3 2026 dividend of $0.3199 per share, continuing 135 quarters of payouts.

Artesian Resources Corporation has announced a quarterly dividend of $0.3199 per share for its Class A and B common stock, payable on August 28, 2026, to shareholders of record by August 17, 2026. This dividend, which represents an annualized payout of $1.2796 per share, …

Organogenesis (ORGO) Earnings Date and Reports 2026

Organogenesis: Q2 Earnings Snapshot

Artesian Resources And 2 Other Top Dividend Stocks To Consider

Artesian Resources (NASDAQ:ARTNA) Posts Earnings Results, Beats Estimates By $0.05 EPS

Phreesia schedules Sept. 2 call to discuss fiscal Q2 results

Genesis Energy (NYSE:GEL) Releases Earnings Results, Beats Expectations By $0.24 EPS

Organogenesis (NASDAQ: ORGO) hit by 58% sales drop and $149M first-half loss

Organogenesis Expects 2026 Revenue Between $179M and $215M